We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » UK Cancer Fund Reverses Course on Some Indications for Novartis’ Afinitor
UK Cancer Fund Reverses Course on Some Indications for Novartis’ Afinitor
NHS England has reinstated two of the three indications for Novartis’ cancer drug Afinitor to its cancer fund, which is use to reimburse cancer therapies not considered cost effective by the National Institute for Health and Care Excellence.